Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Cymabay Therapeutics, Inc. (CBAY)  
$32.48 0.00 (0.00%) as of 4:30 Thu 3/21


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 114,780,000
Market Cap: 3.73(B)
Last Volume: 0 Avg Vol: 0
52 Week Range: $7.47 - $32.48
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   CymaBay Therapeutics is a clinical-stage biopharmaceutical company focused on developing and providing access to therapies for patients with liver and other chronic diseases. Co.'s pipeline includes the following clinical stage product candidates: seladelpar, a selective agonist for the peroxisome proliferator-activated receptor delta, which is a nuclear receptor that regulates genes involved in bile acid/sterol, lipid, and glucose metabolism, and regulation of certain inflammatory cells; and MBX-2982, which targets G protein-coupled receptor 119 (GPR119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 51,301
Total Buy Value $0 $0 $0 $100,037
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 6,000 235,302 552,511 672,611
Total Sell Value $191,849 $4,692,766 $8,944,114 $10,085,429
Total People Sold 1 5 6 7
Total Sell Transactions 1 14 33 36
End Date 2024-02-11 2023-11-10 2023-05-12 2022-05-12

   
Records found: 165
  Page 2 of 7  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Mcwherter Charles President of R&D   •       –      –    2023-12-18 4 OE $5.00 $56,660 D/D 11,332 21,504     -
   Menold Daniel Vice President, Finance   •       –      –    2023-12-15 4 AS $21.98 $472,646 D/D (21,497) 0 47%     
   Menold Daniel Vice President, Finance   •       –      –    2023-12-15 4 OE $4.05 $137,420 D/D 21,497 11,497     -
   Quinlan Paul T General Counsel   •       –      –    2023-12-15 4 AS $21.98 $109,903 D/D (5,000) 0 47%     
   Quinlan Paul T General Counsel   •       –      –    2023-12-15 4 OE $2.94 $14,700 D/D 5,000 5,000     -
   Shah Sujal Chief Executive Officer   •       •      –    2023-12-11 4 AS $19.99 $1,297,170 D/D (64,865) 171,301 58%     
   Shah Sujal Chief Executive Officer   •       •      –    2023-12-11 4 OE $5.00 $324,325 D/D 64,865 172,191     -
   Dorling Janet Director   –       •      –    2023-12-11 4 AS $20.07 $120,422 D/D (6,000) 0 58%     
   Dorling Janet Director   –       •      –    2023-12-11 4 OE $4.63 $27,780 D/D 6,000 6,000     -
   Mcwherter Charles President of R&D   •       –      –    2023-11-17 4 AS $18.28 $207,293 D/D (11,342) 15,000 77%     
   Mcwherter Charles President of R&D   •       –      –    2023-11-17 4 OE $5.00 $56,710 D/D 11,342 26,342     -
   Menold Daniel Vice President, Finance   •       –      –    2023-11-15 4 AS $17.38 $0 D/D (0) 0 80%     
   Menold Daniel Vice President, Finance   •       –      –    2023-11-15 4 OE $3.45 $60,375 D/D 17,500 17,500     -
   Quinlan Paul T General Counsel   •       –      –    2023-11-15 4 AS $17.38 $86,889 D/D (5,000) 0 80%     
   Quinlan Paul T General Counsel   •       –      –    2023-11-15 4 OE $2.94 $14,700 D/D 5,000 5,000     -
   Shah Sujal Chief Executive Officer   •       •      –    2023-11-13 4 AS $15.89 $1,030,660 D/D (64,863) 171,301 93%     
   Shah Sujal Chief Executive Officer   •       •      –    2023-11-13 4 OE $5.00 $324,315 D/D 64,863 192,156     -
   Dorling Janet Director   –       •      –    2023-11-10 4 AS $15.24 $106,700 D/D (7,000) 0 99%     
   Dorling Janet Director   –       •      –    2023-11-10 4 OE $4.63 $32,410 D/D 7,000 7,000     -
   Mcwherter Charles President of R&D   •       –      –    2023-10-18 4 AS $14.07 $305,941 D/D (21,743) 15,000 136%     
   Mcwherter Charles President of R&D   •       –      –    2023-10-18 4 OE $5.00 $108,715 D/D 21,743 36,743     -
   Quinlan Paul T General Counsel   •       –      –    2023-10-16 4 AS $13.76 $68,798 D/D (5,000) 0 124%     
   Quinlan Paul T General Counsel   •       –      –    2023-10-16 4 OE $2.94 $14,700 D/D 5,000 5,000     -
   Menold Daniel Vice President, Finance   •       –      –    2023-10-16 4 AS $13.76 $0 D/D (0) 0 124%     
   Menold Daniel Vice President, Finance   •       –      –    2023-10-16 4 OE $3.45 $60,375 D/D 17,500 17,500     -
  165 Records found
  1  2  3  4  5  6  7   
  Page 2 of 7
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us